Cognitive Dysfunction in Patients with Rheumatic Diseases.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00012711

Enrollment

300

Registered

2018-10-23

Start date

2018-11-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M45 M07.3

Interventions

Group 1: Cognitive function in patients with rheumatic diseases compared to a control group by a computer based assessment of memory and attention. (MAT

memory and attention test

Adler G, Bektas M, Feger M, Lembach Y. [Computer-based assessment of memory and attention: evaluation of the memory and attention test (MAT)]. Psychiatr Prax. 2012 Mar

39(2):79-83.). Documentation of disease characteristics and questionnaires regarding fatigue, physical function, Sleep quality, depressive Symptoms.

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients with rheumatic disease, and comparator group, written consent, age > 18

Exclusion criteria

Exclusion criteria: Inability to consent

Design outcomes

Primary

Measure	Time frame
Differences in cognitive function between patients with rheumatic diseases and control group in a computer-based memory and attention test (MAT) - working memory - short-term memory - selective attention - executive functions	—

Secondary

Measure	Time frame
Differences analyzed e.g. by disease activity (DAPSA, ASDAS), disease duration, physical function (HAQ-DI), pain (VAS pain), depressive symptoms (PHQ-9), fatigue (FACIT-Fatigue / VAS Fatigue), sleep quality (PSQI)	—

Countries

Germany

Contacts

Public ContactStefan Kleinert

Praxisgemeinschaft Rheumatologie – Nephrologie

stefan.kleinert@pgrn.de+49 9131 89 000

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026